about
TEL is a sequence-specific transcriptional repressorInteraction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASSA novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemiaThe TEL gene products: nuclear phosphoproteins with DNA binding propertiesInteraction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA exportExpression of tal-1 and GATA-binding proteins during human hematopoiesisThe JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaTET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).Properties and biological roles of TET proteins during embryogenesis and in hematopoiesisA TEL-JAK2 fusion protein with constitutive kinase activity in human leukemiaOtt1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleenThe transcription factor Srf regulates hematopoietic stem cell adhesionTEL-JAK2 transgenic mice develop T-cell leukemia.CALM-AF10 fusion gene in leukemias: simple and inversion-associated translocation (10;11).A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.Characterization of a novel ETS gene, TELB, encoding a protein structurally and functionally related to TEL.HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis.t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique Hématologique (GFCH).The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.Acquired initiating mutations in early hematopoietic cells of CLL patients.Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.TET proteins and the control of cytosine demethylation in cancer.Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion.NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique.Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Jumping translocations.Chromosome abnormalities of the short arm of chromosome 12 in hematopoietic malignancies: a report including three novel translocations involving the TEL/ETV6 gene.DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in miceSTAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomasNew mutations and pathogenesis of myeloproliferative neoplasms.TET2, a tumor suppressor in hematological disorders.Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia.Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
P50
Q22010632-F50C1A65-52C1-44B7-B8A4-951F24A38265Q24294717-F71E2E3C-005B-4E39-B449-EB299FF0E8F0Q24312040-715846F4-200B-4A91-83EF-6EADEABE6A78Q24316911-1059A0FB-D81B-4D5D-B657-F14384139CE9Q24317404-0918D81B-90B9-4F78-9D89-25851910EE48Q24318695-CDD92331-0B66-4793-9C3E-871B3670D96BQ24337571-5191391B-A746-44EC-813F-908D951FBF9CQ27266125-1844BE1E-9BF2-4E02-A127-19D55B707E9BQ27851480-B35E20D9-72B3-4298-9358-83058EF93AE5Q28085708-4950E814-7064-4D9F-9037-408C5C779778Q28253771-A79A27BA-D3ED-4BB2-8F0B-CB5D82B8F41DQ28588065-47F71E07-DF8E-4C0D-927A-2A04A09F5E1FQ28590745-A6B14FB0-1F04-4110-A33C-0B3B32EEAF7AQ33180502-D1A00E4D-8BC9-4446-BB8C-345F089FCC68Q33181503-B45BB61D-FC4A-4CEC-AEF3-7F3784877BBAQ33182502-FEDB3FC2-2B0C-4BA5-99D6-B2A2CD5E5482Q33921480-D2E026DC-74C9-4DEB-B7A6-1D9A8DCA8745Q34140101-BFA3FAD1-D274-427A-BE69-FB2C09DA7A4CQ34230063-1409A722-F961-41E9-9E28-63AD1AC437F0Q34312960-EC6AE3F1-CB00-43EA-A813-D7373CD638ABQ34424293-E3445279-CD74-436A-B58C-79B5BCFA2DA5Q34480244-ECCDA0A3-CA7D-4B7D-8A0E-01F36F201D5CQ34503575-3C2C4921-B229-4751-A57C-B47468013B72Q35021377-4012BD90-0FC2-4DB5-B788-43E7CBFF374EQ35068764-F55341A4-3A8A-44C7-ADFC-E28A7F6F97BEQ35801750-89240E48-C88D-4633-B25F-1B814B2275ADQ36391820-DFB94CB3-7019-45C1-AB65-0A350472FFBAQ36627526-78AA6F8F-A2FE-4345-BBE3-C1CF74749ADDQ36795685-28A40DBB-9911-41ED-8F23-D9CC38949190Q36883850-A46F4563-3BEA-44C9-AF81-9BC9E1D0FD31Q36908743-FA14F759-97FB-415A-ABFD-A86A0EEE8A27Q37273194-40490370-07A7-4515-91CF-5BC7269362ADQ37612511-F7DDE9D1-A5D4-4EFC-A373-CFC125AA014DQ37886439-BCCD7C75-627A-4500-8C70-FD1858C99A5FQ37975340-D6640F41-0BAD-46B7-AD1B-D5C57B44CF63Q38000919-51AA0BF5-4704-4D39-BABD-ED75D78068CCQ38074757-4478B3FD-D0A7-4D5D-9116-B23988BAD2B4Q38162038-5310D881-898D-42F5-B9F8-D149600AC8C6Q38288856-FE343828-6FDC-4A31-AEC0-317AED4C8185Q38343881-D5FA2ED5-3944-4300-82D8-4214CB96067F
P50
description
biomedical researcher
@en
name
Bernard O
@nl
Olivier Bernard
@en
type
label
Bernard O
@nl
Olivier Bernard
@en
altLabel
Bernard O
@en
prefLabel
Bernard O
@nl
Olivier Bernard
@en
P106
P31
P496
0000-0002-0463-9747